Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

48.32USD
24 Apr 2015
Change (% chg)

$-0.14 (-0.29%)
Prev Close
$48.46
Open
$48.36
Day's High
$48.51
Day's Low
$48.10
Volume
1,031,729
Avg. Vol
1,598,609
52-wk High
$48.62
52-wk Low
$37.78

ABT.N

Chart for ABT.N

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of healthcare products. The Company’s business segments include established pharmaceutical products, which include gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products,... (more)

Overall

Beta: 0.67
Market Cap(Mil.): $72,913.81
Shares Outstanding(Mil.): 1,508.98
Dividend: 0.24
Yield (%): 1.99

Financials

  ABT.N Industry Sector
P/E (TTM): 42.74 41.06 41.71
EPS (TTM): 1.13 -- --
ROI: 5.38 16.86 16.20
ROE: 7.37 17.36 17.00
Search Stocks

Abbott says its payoff from Mylan deal surged

- Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

22 Apr 2015

UPDATE 1-Abbott says its payoff from Mylan deal surged

April 22 - Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

22 Apr 2015

CORRECTED-Abbott says payoff from Mylan deal surges, as Mylan shares leap

April 22 - Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

22 Apr 2015

Abbott profit beats expectations, sales of branded generics jump

- Abbott Laboratories reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions.

22 Apr 2015

UPDATE 1-Abbott profit beats expectations, sales of branded generics jump

April 22 - Abbott Laboratories reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions.

22 Apr 2015

Abbott Labs profit from continuing operations more than doubles

April 22 - Abbott Laboratories' net earnings from continuing operations more than doubled in the first quarter, with strong performance in its branded generics, international nutrition and diagnostics divisions.

22 Apr 2015

Wall St. falls from records, led by technology stocks

NEW YORK - U.S. stocks finished down on Tuesday, a day after the S&P and Dow hit records, and the Nasdaq retreated with technology stocks.

03 Mar 2015

UPDATE 1-Mylan still on the prowl for deals, perhaps one by end 2015

March 2 - U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week.

02 Mar 2015

UPDATE 3-Bidvest makes $515 million bid for rest of Adcock Ingram

* Shares in Adcock jump more than four percent (Adds analyst comment)

23 Feb 2015

Abbott CEO losing no sleep over stronger dollar

- Abbott Laboratories' chief executive officer is not worried about the stronger dollar, telling analysts on Thursday his company will better withstand its painful effects than rivals due to its European factories and growing sales of nutritional products, medical diagnostics and medical optics.

29 Jan 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $101.08 +0.62
Pfizer Inc. (PFE.N) $35.27 -0.09
Novartis AG (NOVN.VX) CHF99.80 -0.80
Merck & Co., Inc. (MRK.N) $57.60 +0.09
Sanofi SA (SASY.PA) €95.86 +0.51
AstraZeneca plc (AZN.L) 4,749.50p -80.50
GlaxoSmithKline plc (GSK.L) 1,534.50p +4.00
Eli Lilly and Co (LLY.N) $71.58 -0.82
Amgen, Inc. (AMGN.OQ) $167.91 -1.26
Boston Scientific Corporation (BSX.N) $18.34 -0.08

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks